Bay1002670、子宮筋腫、安全性と有効性（EU、米国、カナダ、日本）

基本情報

NCT ID: NCT02131662
ステータス: 完了
試験のフェーズ: 第2相
試験タイプ: 介入
目標被験者数: 309
治験依頼者名: Bayer

概要

The study is performed to assess the efficacy and safety of different doses of BAY1002670 in subjects with uterine fibroids. The dose-response relationship will be evaluated. Further, the study aims to establish a population pharmacokinetic/pharmacodynamic relationship for BAY1002670 in subjects with uterine fibroids. To assess the efficacy of BAY1002670 the interchangeability of menstrual pictogram and alkaline hematin method for the judgement of menstrual blood loss will be assessed.

対象疾患

Leiomyoma

介入

BAY1002670(DRUG)

Placebo(DRUG)

依頼者（Sponsor）

バイエル薬品株式会社(INDUSTRY)